In a phase II study to investigate the pharmacokinetics, pharmacokinetic data were collected in children who received
10 mg bilastine once daily as a melting tablet (31 children aged 4 to 11 years with allergic rhinoconjunctivitis or chronic urticaria). Pharmacokinetic analysis of plasma concentration data showed that paediatric dosing of 10 mg bilastine once daily resulted in comparable systemic exposure to that observed after a 20 mg dose in adults and adolescents (mean AUC 1014 ng × h/ml in children aged 6 to 11 years). [SmPC Allegra]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Allergic rhinoconjunctivitis and urticaria |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Common (1-10%): Rhinitis, headache, allergic conjunctivitis, abdominal pain/pain in the upper abdomen
Occasional (0.1-1 %): Dizziness, loss of consciousness, eye irritation, diarrhoea, nausea, swollen lip, eczema, urticaria, fatigue
[SmPC Allegra®]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Aminoalkyl ethers | ||
|---|---|---|
| R06AA04 | ||
| R06AA52 | ||
| R06AA02 | ||
| Substituted alkylamines | ||
|---|---|---|
| R06AB03 | ||
| Phenothiazine derivatives | ||
|---|---|---|
| R06AD01 | ||
| R06AD08 | ||
| R06AD02 | ||
| Piperazine derivatives | ||
|---|---|---|
| R06AE07 | ||
| R06AE03 | ||
| R06AE09 | ||
| R06AE05 | ||
| Other antihistamines for systemic use | ||
|---|---|---|
| R06AX18 | ||
| R06AX02 | ||
| R06AX27 | ||
| R06AX26 | ||
| R06AX17 | ||
| R06AX13 | ||
| R06AX25 | ||
| R06AX28 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.